



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**9 November 2018**

---

## **Recapitalisation led by major US-based biotechnology investor**

### ***Follow-on Share Purchase Plan***

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announced a recapitalisation of the company led by a major US-based biotechnology investor and Bionomics' largest shareholder BVF Partners L.P.

The recapitalisation, via a placement of 48,097,158 shares at \$0.1637 per share to BVF and affiliated funds, raising A\$7,873,505. The placement price represents a premium of 10% to the volume-weighted average price of Bionomics shares in the past 5 day period.

Bionomics' Executive Chairman Dr Errol De Souza commented "We are pleased to have the support of a world-class specialist investor in the capital raise. This funding along with our ongoing cost cutting efforts are expected to provide Bionomics with the strategic flexibility to maximise shareholder returns from Bionomics' existing partnership with Merck & Co. (known as MSD outside the United States and Canada) as well as from its remaining research and development assets."

Following completion of the placement BVF's holding in Bionomics will increase from approximately 10.02% to approximately 19.9% of issued capital, and BVF will be invited to nominate a director to the Board of Bionomics. A curriculum vitae of BVF's intended nominee, Mr Mitch Kaye, is attached as an appendix.

Bionomics' institutional shareholders will be given an opportunity to participate in the recapitalisation by way of an institutional placement up to the limit of Bionomics' remaining placement capacity (being 5% of issued capital) to raise up to a further \$3,984,183 at \$0.1637, further details of which will be provided in a separate announcement. BVF (or affiliates) will be entitled to take up any shares not taken up in the placement (subject to Corporations Act limitations).

Retail investors will be given an opportunity to participate in a share purchase plan at a price of \$0.1550, subject to a cap of 2.5% of issued capital post-placements (and scale back), further details of which will also be provided in a separate announcement.

## FOR FURTHER INFORMATION PLEASE CONTACT:

### Australia

Monsoon Communications

Rudi Michelson

+613 9620 3333

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

### US

Stern Investor Relations

Will O'Connor

+1 212 362 1200

[will@sternir.com](mailto:will@sternir.com)

### About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)

### Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

## Appendix

MITCHELL KAYE, Chief Operating Officer

Mitchell Kaye, J.D., joined BVF Partners L.P. in 2013. Mr. Kaye was the founding member of Xmark Opportunity Partners, LLC, an investment fund exclusively focused on investments in publicly traded life sciences companies and was also a founding member of Brown Simpson Asset Management, LLC, an investment fund that was at the forefront of private placement investing in the public markets. He ran these two funds from 2001-2008 and 1996-2001, respectively. Mr. Kaye was the Founder of MedClaims Liaison, LLC, a consumer advocacy business, and served as its Chief Executive Officer from its inception in 2010 until he joined BVF. From 2008-2010, Mr. Kaye was a Managing Director with Navigant Capital Advisors, a financial and strategic advisory services firm, and head of Navigant's Financial Institutions Restructuring Solutions Team. Mr. Kaye has served on the boards of several private and public companies, and also served on the board of the New York Alzheimer's Association. Mr. Kaye received his B.A. from Wesleyan University, and his J.D. from Northwestern University School of Law.